[1]顾树江a,张春铭b,盛　利a,等.高血压肾病患者血清尿调节蛋白和胱抑素 C水平与临床病理特征及预后的相关性研究[J].现代检验医学杂志,2022,37(01):61-66.[doi:10.3969/j.issn.1671-7414.2022.01.013]
　GU Shu-jianga,ZHANG Chun-mingb,SHENG Lia,et al.Correlation Study on Serum Uromodulin and Cystatin C Levels with Clinicopathological Characteristics and Prognosis inPatients with Hypertensive Nephropathy[J].Journal of Modern Laboratory Medicine,2022,37(01):61-66.[doi:10.3969/j.issn.1671-7414.2022.01.013]
点击复制

高血压肾病患者血清尿调节蛋白和胱抑素 C水平与临床病理特征及预后的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年01期
页码:
61-66
栏目:
论　著
出版日期:
2022-01-15

文章信息/Info

Title:
Correlation Study on Serum Uromodulin and Cystatin C Levels with Clinicopathological Characteristics and Prognosis inPatients with Hypertensive Nephropathy
文章编号:
1671-7414（2022）01-061-06
作者:
顾树江1a; 张春铭1b; 盛　利1a; 付祎帆1a; 张　艳1c; 韩呈武2
(1. 北京市昌平区中医医院a 检验科;b. 脾胃病科;c. 病理科，北京 112200; 2. 中日友好医院检验科, 北京 100029)
Author(s):
GU Shu-jiang1a;  ZHANG Chun-ming1b;  SHENG Li1a;  FU Yi-fan1a;  ZHANG Yan1c;  HAN Cheng-wu2
（1a.Department of Laboratory Medicine;1b.Department of Spleen and Stomach Diseases;1c.Department of Pathology,Beijing Changping District Hospital of Traditional Chinese Medicine, Beijing 102200,China; 2. Department ofLaboratory Medicine，China-Japan Friendship Hospital, Beijing 102200,China）
关键词:
尿调节蛋白; 胱抑素 C; 高血压肾病; 病理特征
分类号:
R587.2；R446.112
DOI:
10.3969/j.issn.1671-7414.2022.01.013
文献标志码:
A
摘要:
目的　探讨高血压肾病患者血清尿调节蛋白（ UMOD）和胱抑素 C（Cys C）水平特点，分析 UMOD，Cys C与临床病理特征和预后的关系。方法　选择 2016年 2月 1日 ~2019年 12月 31日北京市昌平区中医医院收治的 149例高血压肾病患者（肾病组）和 92例体检志愿者（对照组），检测血清 UMOD，Cys C，尿素氮（ BUN）和血肌酐（SCr）水平，计算肾小球滤过率（ eGFR），分析 UMOD，Cys C与 BUN，SCr，eGFR之间的相关性。肾病组给予 B超引导下行肾穿刺活检获取肾组织病理学特征，比较不同病理特征间血清 UMOD，Cys C水平差异。随访肾病组患者，Kaplan-Meier绘制不同 UMOD，Cys C水平下高血压肾病患者生存曲线， Cox比例风险模型分析影响高血压肾病患者发生终末期肾病（ ESRD）的因素。结果　肾病组血清 UMOD（126.49±32.15ng/ml vs 158.26±45.92ng/ml），eGFR
Abstract:
Objective　To investigate the characteristics of serum uromodulin (UMOD) and cystatin C (Cys C) levels in patientswith hypertensive nephropathy, and analyze the relationship between UMOD and Cys C, and clinicopathological characteristicsand prognosis. Methods　149 patients with hypertensive nephropathy who were admitted to the Beijing Changping DistrictHospital of Traditional Chinese Medicine from February 1 to 2016 and December 31, 2019 (nephropathy group) and 92volunteers (control group) were selected. Serum levels of UMOD, Cys C, urea nitrogen (BUN) and serum creatinine (SCR) weredetected, and the glomerular filtration rate (eGFR) was calculated. The correlation between UMOD, Cys C and BUN, SCR andEGFR were analyzed. Kidney biopsy guided by B-ultrasound was performed in the nephropathy group to obtain thehistopathological characteristics of the kidney, and the differences in serum UMOD and Cys C levels among differentpathological characteristics were compared. Patients in the nephropathy group were followed up. Kaplan-Meier drew survivalcurves of patients with different UMOD and Cys C levels, and Cox proportional risk model was used to analyze the factorsaffecting the occurrence of end-stage renal disease (ESRD) in patients with nephropathy. Results　The levels of serum UMOD（126.49±32.15ng/ml vs 158.26±45.92ng/ml） and eGFR（60.35±16.31ml/min/1.73m2 vs 121.38±12.06ml/min/1.73m2）in nephropathy group were lower than those in control group (t=5.291，28.449，all P < 0.05), and the levels of Cys C（2.43±0.65ng/ml vs 0.73±0.29ng/ml）, BUN（35.26±6.32mmol/L vs 13.02±2.43mmol/L） and Scr（165.23±25.16μmol/L vs 25.11±5.07μmol/L） were higher than those in control group (t=22.758, 31.344, 52.292, all P < 0.05), the differenceswere statistically significant, repectively. UMOD level was negatively correlated with BUN and Scr (r=-0.769, -0.795, P < 0.05),and positively correlated with EGFR (r=0.842, P < 0.05). Cys C level was positively correlated with BUN and Scr (r=0.767,0.757, all P < 0.05), and negatively correlated with EGFR (r=-0.812, P < 0.05). The serum UMOD level in patients with crescentformation and moderate to severe tubuloatrophy/interstitial fibrosis was lower than that in patients without crescent formation,and in patients with mild tubuloatrophy/interstitial fibrosis (t=12.056, 18.081, all P < 0.05), the level of serum Cys C in patientswith glomerular sclerosis, segmental sclerosis and glomerular ischemia wrinkle was higher than that in patients withoutglomerular sclerosis, segmental sclerosis and glomerular ischemia wrinkle (t=26.668, 19.508, 17.985, all P < 0.05), thedifferences were statistically significant, respectively. The renal survival rate of patients with low level of UMOD and high levelof Cys C was lower than that of patients with high level of UMOD and low level of Cys C (Log Rank χ2=7.960, 4.683, all P <0.05). Tubule atrophy, interstitial fibrosis, low UMOD and high Cys C were risk factors for ESRD in patients with hypertensivenephropathy (all P < 0.05). Conclusion　The level of serum UMOD decreased and Cys C increased in patients with hypertensivenephropathy. Both UMOD and Cys C are related to the pathological characteristics of renal tissue and the occurrence of ESRD.

参考文献/References:

[1] 汪隆海, 张求霞, 黄飞, 等. 尿液10 项生化指标联合检测及优化对高血压肾病的诊断价值研究[J]．现代检验医学杂志, 2020, 35(4):82-86, 112．WANG Longhai, ZHANG Qiuxia, HUANG Fei, et al.Study on the combined detection and optimization ofurine 10 biochemical indexes in the diagnosis valueof hypertensive nephropathy [J]. Journal of ModernLaboratory Medicine, 2020, 35(4): 82-86, 112.
[2] 荀春华, 赵勇, 王文娟, 等. 血清视黄醇结合蛋白4和尿调节素对慢性肾病的诊断价值[J]. 中国卫生检验杂志, 2017,27(10):1442-1444.XUN Chunhua,ZHAO Yong,WANG Wenjuan,etal. Diagnostic value of sera retinol binding protein4 and uromodulin for chronic kidney disease[J].Chinese Journal of Health Laboratory Technology,2017,27(10):1442-1444.
[3] 占小锋, 汪妍, 张长磊, 等. 胱抑素C 与CKD-EPI2012 在老年高血压肾损伤患者中的研究进展[J]. 中国心血管杂志, 2020,25(3):274-277.ZHAN Xiaofeng,WANG Yan, ZHANG Changlei,et al.Research progress of cystatin C and CKD-EPI 2012injury [J]. Chinese Journal of Cardiovascular Medicine,2020,25(3):274-277.
[4] 中国高血压防治指南修订委员会. 中国高血压防治指南2010[J]. 中华高血压杂志, 2011,19(8):701-743.Writing Group of 2010 Chinese Guidelines for theManagement of Hypertension. 2010 Chinese guidelinesfor the management of hypertension [J].Chinese Journalof Hypertension, 2011,19(8):701-743.
[5] 程莹，李宁娜，游志清，等．三种CKD-EPI 公式与改良MDRD 公式诊断糖尿病肾病一致性分析[J].中国全科医学,2016,19(29):3584-3588.CHENG Ying,LI Ningna,YOU Zhiqing,et al. Diagnosisof consistency between three CKD-EPI and modifiedMDRD equations for diabetic kidney disease in patientswith type 2 diabetes mellitus[J].Chinese GeneralPractice, 2016,19(29):3584-3588.
[6] SOLEZ K, RACUSEN L C. The Banff classificationrevisited[J]. Kidney International, 2013, 83(2): 201-206.
[7] 梁少姗, 乐伟波, 梁丹丹, 等. 高血压肾损害的临床病理特点及预后[J]. 肾脏病与透析肾移植杂志,2015, 24(1):32-37.LIANG Shaoshan,LE Weibo,LIANG Dandan,et al.Clinico-pathological characteristics and outcomeof patients with biopsy-proven hypertensivenephrosclerosis[J]. Chinese Journal of Nephrology,Dialysis & Transplantation, 2015,24(1):32-37.
[8] 杨雄，尹爱萍．慢性肾脏病患者血液中FGF23,TNF-α,RANTES 和IL-12 检测水平的相关性研究[J]．现代检验医学杂志, 2020,35(1):25-28.YANG Xiong,YIN Aiping. Correlation betweenFGF23, TNF-α, RANTES and IL-12 levels in theblood of patients with chronic kidney disease[J].Journalof Modern Laboratory Medicine , 2020,35(1):25-28.
[9] DEVUYST O, BOCHUD M.Uromodulin kidneyfunction,cardiovascular disease,and mortality [J].Kidney International, 2015, 88(5): 944-946.
[10] MAO Weipu, LIU Shenghua, WANG Keyi, et al.Cystatin C in evaluating renal function in ureteralcalculi hydronephrosis in adults[J]. Kidney & BloodPressure Research, 2020, 45(1): 109-121.
[11] GARIMELLA P S, JABER B L, TIGHIOUART H, etal. Association of preoperative urinary uromodulin withAKI after cardiac surgery[J]. Clinical Journal of theAmerican Society of Nephrology, 2017, 12(1): 10-18.
[12] ZHOU Jingjing, CHEN Yuqing, LIU Ying, et al.Urinary uromodulin excretion predicts progressionof chronic kidney disease resulting from IgAnephropathy[J]. PLoS One, 2013, 8(8): e71023.
[13] 杨秀莲，张成磊，岳晋巍，等．原发性高血压早期肾损害与血清25- 羟维生素D 和 同型半胱氨酸相关性分析[J]. 宁夏医科大学学报,2019,41(4):359-363.YANG Xiulian,ZHANG Chenglei,YUE Jinwei,etal. Corrleation analysis between serum 25（OH）Dand homocysteine in early renal damage of essentialhypertension patients [J].Journal of Ningxia MedicalUniversity,2019,41(4):359-363.
[14] 朱华芳，陈光利，黄娟，等．血清胱抑素C 在老年高血压患者早期肾损害中的诊断价值分析[J]．临床检验杂志( 电子版) ,2019,8(4):19-20.ZHU Huafang,CHEN Guangli,HUANG Juan,et al.Diagnostic value of serum cystatin C in early stagerenal impairment in elderly hypertensive patients[J].Chinese Journal of Clinical Laboratory Science(Electronic),2019,8(4):19-20.
[15] NQEBELELE N U, DICKENS C, DIX-PEEK T, etal. Urinary uromodulin levels and UMOD variants inBlack South Africans with Hypertension-Attributedchronic kidney disease[J]. International Journal ofNephrology, 2019,2019: 8094049.
[16] 汤海波, 张晓斌, 闫红, 等. 血清胱抑素C 在早期急性肾损伤诊断中的价值[J]．河北医药，2016，38(24):3752-3754, 3757.TANG Haibo,ZHANG Xiaobin,YAN Hong,et al.Valueof serum cystatin C in the diagnosis of early acutekidney injury[J]. Hebei Medical, Journal 2016, 38 (24):3752-3754,3757.
[17] TACHIBANA S, IYODA M, SUZUKI T, et al.Serum uromodulin is associated with the severityof clinicopathological findings in ANCA-associatedglomerulonephritis[J]. PLoS One, 2019, 14(11):e0224690.
[18] CAETANO E R,ZATZ R, SALDANHA L B,et al.Hypertensive nephrosclerosis as a relevant cause of chronicrenal failure[J]. Hypertension, 2001,38(2): 171-176.
[19] 张旦欢, 毛佩菊, 黄燕萍. 胱抑素C 与肾功能损害程度相关性研究[J/CD]. 中华临床医师杂志( 电子版),2012,6(8):162-164.ZHANG Danhuan,MAO Peiju, HUANG Yanping,etal.Study on the correlation between cystatin C andthe degree of renal function impairment[J/CD].Chinese Journal of Clinicians (Electronic Edition),2012,6(8):162-164.
[20] LEVIN A, STEVENS P E. Summary of KDIGO2012 CKD guideline:behind the scenes,need forguidance,and a framework for moving forward[J].Kidney International, 2014, 85(1): 49-61.
[21] CHEN Tingyu, WANG Qianliao, LI Guisen, et al.A single nucleotide polymorphism in the UMODpromoter is associated with end stage renal disease[J].BMC Medical Genetics, 2016, 17(1): 95.
[22] 董海芸, 金石昆, 黄静蓉, 等. 慢性肾衰竭患者CysC,β2-MG,Hcy 的检测及其相关性分析[J]. 标记免疫分析与临床, 2019, 26(2):314-317.DONG Haiyun,JIN Shikun,HUANG Jingrong,et al.Detection of Cys C,β2-MG and Hcy in patients withchronic renal failure and their correlation analysis[J]. Labeled Immunoassays and Clinical Medicine,2019,26(2):314-317.
[23] 马秋波, 包宇实. 慢性肾脏病肾间质纤维化免疫机制研究进展[J]. 中华实用诊断与治疗杂志, 2018, 32(1):101-104.MA Qiubo,BAO Yushi. Advances of immunemechanisms of renal interstitial fibrosis in chronickidney disease [J]. Journal of Chinese PracticalDiagnosis and Therapy, 2018,32(1):101-104.

相似文献/References:

[1]罗 武a,马琼卉a,刘 兴a,等.新型冠状病毒肺炎并发急性肾损伤患者血清胱抑素C，尿素氮和肌酐水平变化及临床价值研究[J].现代检验医学杂志,2023,38(02):194.[doi:10.3969/j.issn.1671-7414.2023.02.037 ]
　LUO Wua,MA Qiong-huia,LIU Xinga,et al.Variation of Level，Risk Factors and Clinical Value Research of Serum Cystatin C, Blood Urea Nitrogen and Creatinine in Patients with COVID-19 Complicated with Acute Kidney Injury[J].Journal of Modern Laboratory Medicine,2023,38(01):194.[doi:10.3969/j.issn.1671-7414.2023.02.037 ]

备注/Memo

备注/Memo:
作者简介：顾树江（1981-），男，研究生，副主任技师，研究方向：临床免疫、生化、出凝血检验，E-mail:gshujiang1981@sina.com。
更新日期/Last Update: 1900-01-01